Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
First Claim
Patent Images
1. A method for improving cognitive function comprising:
- selecting a patient, andadministering to the patient montelukast sodium in a solid dosage form, the solid dosage form comprising a therapeutically effective amount of montelukast sodium, wherein the amount of montelukast sodium is greater than about 20 mg, anda rate release modifier, wherein the rate release modifier provides the patient a controlled release of montelukast sodium for at least about 4 hours.
0 Assignments
0 Petitions
Accused Products
Abstract
A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of montelukast in an immediate release and sustained release is also disclosed.
35 Citations
18 Claims
-
1. A method for improving cognitive function comprising:
-
selecting a patient, and administering to the patient montelukast sodium in a solid dosage form, the solid dosage form comprising a therapeutically effective amount of montelukast sodium, wherein the amount of montelukast sodium is greater than about 20 mg, and a rate release modifier, wherein the rate release modifier provides the patient a controlled release of montelukast sodium for at least about 4 hours. - View Dependent Claims (12, 13, 14, 16)
-
-
2. A method for improving cognitive function comprising:
-
selecting a patient, and administering to the patient a modified release solid dosage form of montelukast sodium having two portions, wherein a first portion comprises a first quantity of at least 5 mg of montelukast sodium in an immediate release formulation and, a second portion comprises a second quantity of at least 10 mg of montelukast sodium in a release-delaying matrix, wherein the total amount of montelukast sodium is at least about 20 mg. - View Dependent Claims (3, 4, 5, 6, 7, 8, 15, 17)
-
-
9. A method for improving cognitive function comprising:
-
selecting a patient, and administering to the patient a multi-particulate pharmaceutical solid dosage form of a montelukast sodium providing a modified release profile comprising a population of immediate release beads comprising montelukast sodium, a population of extended release beads, wherein said extended release beads comprise a montelukast sodium core particle and an extended release coating, wherein the multi-particulate pharmaceutical dosage form of a montelukast sodium comprises at least about 20 mg of montelukast sodium in combined immediate release beads and extended release beads. - View Dependent Claims (10, 11, 18)
-
Specification